Hematology, Transfusion and Cell Therapy (Apr 2020)
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
- Guilherme Fleury Perini,
- Thais Fischer,
- Rafael Dezen Gaiolla,
- Talita Bueno Rocha,
- Marcelo Bellesso,
- Larissa Lane Cardoso Teixeira,
- Marcia Torresan Delamain,
- Adriana Alves de Souza Scheliga,
- Glaciano Nogueira Ribeiro,
- Jorge Vaz Neto,
- Otávio Cesar Carvalho Guimaraes Baiocchi,
- André Neder Ramires Abdo,
- Celso Arrais-Rodrigues,
- Laura M. Fogliatto,
- Ricardo de Sá Bigni,
- Rony Schaffel,
- Irene Biasoli,
- Juliana Pereira,
- Samir Kanaan Nabhan,
- Cármino Antônio de Souza,
- Carlos Sérgio Chiattone
Affiliations
- Guilherme Fleury Perini
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Américas Oncologia, São Paulo, SP, Brazil; Corresponding author at: Centro de Oncologia e Hematologia Familia Dayan-Daycoval, Hospital Israelita Albert Eintein, Av. Albert Einstein, 627/701, Bloco A, 3o Subsolo, CEP: 05651901, São Paulo, SP, Brazil.
- Thais Fischer
- AC Camargo Cancer Center, São Paulo, SP, Brazil
- Rafael Dezen Gaiolla
- Hospital das Clínicas da Faculdade de Medicina de Botucatu (HC-FMB), São Paulo, SP, Brazil
- Talita Bueno Rocha
- AC Camargo Cancer Center, São Paulo, SP, Brazil
- Marcelo Bellesso
- Instituto do Cancer de São Paulo, (ICESP), São Paulo, SP, Brazil; Hemomed, São Paulo, SP, Brazil
- Larissa Lane Cardoso Teixeira
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Hospital Municipal da Vila Santa Catarina, São Paulo, SP, Brazil
- Marcia Torresan Delamain
- Américas Oncologia, São Paulo, SP, Brazil; Universidade de Campinas (UNICAMP), Campinas, SP, Brazil
- Adriana Alves de Souza Scheliga
- Grupo Oncoclínicas - CTO/CEON, Rio de Janeiro, RJ, Brazil
- Glaciano Nogueira Ribeiro
- Hospital das Clínicas da Universidade Federal de Minas Gerais (HC UFMG), Belo Horizonte, MG, Brazil
- Jorge Vaz Neto
- Centro de Cancer de Brasilia CETTRO, Brasilia, DF, Brazil
- Otávio Cesar Carvalho Guimaraes Baiocchi
- Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil; Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil
- André Neder Ramires Abdo
- Instituto do Cancer de São Paulo, (ICESP), São Paulo, SP, Brazil; Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil
- Celso Arrais-Rodrigues
- Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil; Hospital Sírio Libanês, São Paulo, SP, Brazil
- Laura M. Fogliatto
- Hospital de Clínicas de Porto Alegre (HPCA), Porto Alegre, RS, Brazil
- Ricardo de Sá Bigni
- Instituto Nacional do Cancer (INCA), Rio de Janeiro, RJ, Brazil
- Rony Schaffel
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Irene Biasoli
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
- Juliana Pereira
- Instituto do Cancer de São Paulo, (ICESP), São Paulo, SP, Brazil
- Samir Kanaan Nabhan
- Universidade Federal do Paraná (UFPR), Paraná, PR, Brazil
- Cármino Antônio de Souza
- Universidade de Campinas (UNICAMP), Campinas, SP, Brazil
- Carlos Sérgio Chiattone
- FCM da Santa Casa de São Paulo, São Paulo, SP, Brazil; Hospital Samaritano Higienópolis, São Paulo, SP, Brazil
- Journal volume & issue
-
Vol. 42,
no. 2
pp. 103 – 110
Abstract
The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.
